| | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a694019 |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | VD: 20-30 Liters |
| Metabolism | Oxidative O-demethylation, followed by conjugation with glucuronide or sulfate |
| Elimination half-life | 11 to 12 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H23N5O3 |
| Molar mass | 369.425 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Trimetrexate is a quinazoline derivative. It is a dihydrofolate reductase inhibitor. [1]
It has been used with leucovorin in treating pneumocystis pneumonia. [2]
It has been investigated for use in treating leiomyosarcoma. [3] It is a methotrexate (MTX) analog that is active against transport-deficient MTX-resistant tumor cells that overcome the acquired and natural resistance to methotrexate. Other uses include skin lymphoma. [4]